Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal's Investor Relations Site, Events and Presentations.
賓夕法尼亞州康肖霍肯，2025年1月3日（環球新聞網）-- Madrigal Pharmaceuticals, Inc.（納斯達克：MDGL）今天宣佈，公司將在2025年1月15日星期三下午2:15（太平洋時間）出席第43屆J.P.摩根醫療健康大會。該演示將實時 webcast，您可以在此訪問或通過訪問Madrigal的投資者關係網站、活動和演示進行訪問。
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit .
關於Madrigal
Madrigal Pharmaceuticals, Inc.（納斯達克：MDGL）是一家生物製藥公司，專注於爲代謝功能障礙相關性脂肪肝炎（MASH）提供新型治療方案，這是一種需求未滿足的肝病。Madrigal的藥物Rezdiffra（resmetirom）是一種每日一次、口服的、針對肝臟的THR-β激動劑，旨在針對MASH的關鍵潛在原因。欲了解更多信息，請訪問。
Investor Contact
Tina Ventura, [email protected]
投資者聯繫
蒂娜·文圖拉，[email protected]
Media Contact
Christopher Frates, [email protected]
媒體聯繫
克里斯托弗·弗雷特斯，[email protected]
Source: Madrigal Pharmaceuticals, Inc.
來源：Madrigal Pharmaceuticals公司。
譯文內容由第三人軟體翻譯。
